CEO of Novocure Ltd (NASDAQ:NVCR) Asaf Danziger sold 100,000 shares of NVCR on 03/01/2019 at an average price of $55.57 a share. The total sale was $5.6 million.
NovoCure Ltd is a medical systems developer in the United States. Its primary product is the TTFields delivery system, which is a low-intensity therapy to combat acute tumors. NovoCure Ltd has a market cap of $5.02 billion; its shares were traded at around $52.85 with and P/S ratio of 19.58. NovoCure Ltd had annual average EBITDA growth of 26.90% over the past five years.
CEO Recent Trades:
CEO Asaf Danziger sold 100,000 shares of NVCR stock on 03/01/2019 at the average price of $55.57. The price of the stock has decreased by 4.89% since.CEO Asaf Danziger sold 903 shares of NVCR stock on 02/28/2019 at the average price of $54.4. The price of the stock has decreased by 2.85% since.CEO Asaf Danziger sold 50,000 shares of NVCR stock on 02/13/2019 at the average price of $51.46. The price of the stock has increased by 2.7% since.CFO Recent Trades:
Hot Medical Stocks To Invest In 2019: TG Therapeutics, Inc.(TGTX)
Advisors' Opinion:- [By Ethan Ryder]
Get a free copy of the Zacks research report on TG Therapeutics (TGTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Todd Campbell]
After reporting solid safety results for umbralisib as a monotherapy in chronic lymphocytic leukemia (CLL) patients who are intolerant to prior BTK (Imbruvica) or PI3K delta inhibitor (Zydelig) therapy, TG Therapeutics (NASDAQ:TGTX) 10.8% on Monday.
- [By Paul Ausick]
TG Therapeutics Inc. (NASDAQ: TGTX) dropped about 40% Tuesday to set a new 52-week low of $5.50. Shares closed at $9.25 on Monday and the stock’s 52-week high is $17.35. Volume was about 70% higher than the daily average of around 7.4 million. The company said it is no longer considering an accelerated application for a clinical drug trial.
Hot Medical Stocks To Invest In 2019: Monsanto Company(MON)
Advisors' Opinion:- [By Chris Lange]
Monsanto Co. (NYSE: MON) is expected to share its most recent quarterly numbers first thing Thursday. Analysts are looking for $0.42 in earnings per share (EPS) and $2.77 billion in revenue. Shares were last seen at $116.78 apiece, in a 52-week range of $104.77 to $122.80. The consensus price target is $125.18.
- [By Max Byerly]
Monsanto (NYSE:MON) was downgraded by equities research analysts at Argus from a “buy” rating to a “sell” rating in a research note issued to investors on Monday, The Fly reports.
- [By Ethan Ryder]
Media headlines about Monsanto (NYSE:MON) have been trending positive on Saturday, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Monsanto earned a media sentiment score of 0.26 on Accern’s scale. Accern also assigned media headlines about the basic materials company an impact score of 44.3437931403927 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Hot Medical Stocks To Invest In 2019: SteadyMed Ltd.(STDY)
Advisors' Opinion:- [By Stephan Byrd]
Steadymed Ltd (NASDAQ:STDY) CEO Jonathan Rigby sold 88,831 shares of the company’s stock in a transaction on Friday, August 17th. The stock was sold at an average price of $4.66, for a total transaction of $413,952.46. Following the completion of the sale, the chief executive officer now owns 41,605 shares of the company’s stock, valued at $193,879.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Hot Medical Stocks To Invest In 2019: Eli Lilly and Company(LLY)
Advisors' Opinion:- [By Chris Lange]
Eli Lilly and Co.'s (NYSE: LLY) short interest shrank to 9.45 million shares from the previous 11.05 million. The stock was trading at $115.45. The 52-week range is $73.69 to $116.61.
- [By Todd Campbell]
Nektar Therapeutics is also working with Eli Lilly (NYSE:LLY) on NKTR-358, a potential treatment for autoimmune diseases that's in phase 1 trials. Last summer, Lilly paid $150 million up front, and it agreed to pay up to $250 million on additional development and regulatory milestones to work with Nektar Therapeutics on the drug.
- [By Chris Lange]
Eli Lilly and Co.'s (NYSE: LLY) short interest decreased to 28.03 million shares from the previous 30.27 million. The stock was trading at $118.01. The 52-week range is $74.51 to $121.84.
- [By Cory Renauer]
AbbVie thinks upadacitinib can add around $6.5 billion to the company's top line at its peak, which looks a bit more achievable following Eli Lilly's (NYSE:LLY) recent date at the FDA. The agency called together an independent panel of experts to discuss a once-rejected application for baricitinib, a therapy similar to upadacitinib that's already generating significant sales in the EU. There were a lot of ins and outs to consider, but I expect the regulator will insist on another lengthy study for Lilly's drug that will clear the runway for upadacitinib's potential launch in 2019.
- [By Todd Campbell]
Many drugmakers market these diabetes drugs, however, Novo Nordisk's, Eli Lilly's, and Sanofi's drugs are among the most widely used treatments. Each generates billions of dollars per year in sales from diabetes drugs, including insulin. The table below shows their 2017 annual results.
Company Market Cap Total Revenue Total Net Income Diabetes-Related Revenue Change in Diabetes Revenue (YOY) Novo Nordisk (NYSE:NVO) $119 billion $17 billion $6 billion $14.7 billion 4% Eli Lilly (NYSE:LLY) $88.5 billion $22.9 billion $4.5 billion $10.1 billion 25% Sanofi (NYSE:SNY) $96.7 billion $41 billion $8.26 billion $5.8 billion (14%)Data sources: Yahoo! Finance and company annual reports. Note: 1. Novo Nordisk's results reflect exchange rates on May 17, 2018. 2. Eli Lilly's net income figure is adjusted net income. 3. Sanofi's net income is business net income, a non-GAAP adjusted figure and results reflect exchange rates on May 17, 2018. YOY = year over year.
Hot Medical Stocks To Invest In 2019: NRG Energy Inc.(NRG)
Advisors' Opinion:- [By Jon C. Ogg]
NRG Energy Inc. (NYSE: NRG) was started with a Buy rating and assigned a $37 price objective (versus a $33.15 close) at Merrill Lynch.
Oasis Petroleum Corp. (NYSE: OAS) was reiterated as Overweight and the target price was raised to $17 from $13 at Morgan Stanley.
- [By Stephan Byrd]
Energi (CURRENCY:NRG) traded up 0.2% against the U.S. dollar during the twenty-four hour period ending at 19:00 PM Eastern on September 15th. Over the last seven days, Energi has traded 14.2% higher against the U.S. dollar. Energi has a market capitalization of $1.61 million and $2,597.00 worth of Energi was traded on exchanges in the last 24 hours. One Energi coin can now be purchased for $0.32 or 0.00004969 BTC on exchanges including CoinExchange, Cryptopia and CryptoBridge.
- [By Shane Hupp]
Energi (CURRENCY:NRG) traded 3.8% lower against the dollar during the 24-hour period ending at 22:00 PM Eastern on February 2nd. Energi has a market cap of $9.51 million and approximately $100,521.00 worth of Energi was traded on exchanges in the last day. One Energi coin can currently be bought for approximately $0.76 or 0.00021720 BTC on major cryptocurrency exchanges including CoinExchange, Cryptopia and CryptoBridge. In the last seven days, Energi has traded down 9.3% against the dollar.
No comments:
Post a Comment